Mesoblast Set To File BLA For Ryoncil With FDA Next Week

RTTNewsJul 1 17:33

Mesoblast to Submit FDA Application for Ryoncil in Treating Pediatric GVHD

Mesoblast Limited (NASDAQ:MESO, ASX:MSB))))), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for ap

BenzingaJul 1 14:57

High Insider Ownership Growth Stocks On The ASX In June 2024

Yahoo FinanceJun 14 11:35

Cantor Fitzgerald Reiterates Overweight on Mesoblast

Cantor Fitzgerald analyst Louise Chen reiterates Mesoblast (NASDAQ:MESO) with a Overweight.

BenzingaJun 5 01:22

Mesoblast Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/04/2024 — Cantor Fitzgerald Reiterates → Overweight 09/21/2023 133.52% Cantor Fitzgerald → $17 Reitera

BenzingaJun 5 01:20

Mesoblast Targets FDA Approval With Ryoncil

TipRanksJun 3 09:27